Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2021-09-09 00:00:00 ET · period of report 2021-09-07 · accession 0001415889-21-004306 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-09 | 2021-09-07+ | OLMA | Bohen Sean | Pres AND CEO, Dir | S - Sale+OE | $30.01 | -3,044 | 52.5K | -5% | -$91.4K |
| DM | 2021-09-09 | 2021-09-07+ | OLMA | Bohen Sean | Pres AND CEO, Dir | M - OptEx | $4.82 | +3,044 | 56.9K | +6% | +$14.7K |
| DM | 2021-09-09 | 2021-09-07+ | OLMA | Bohen Sean | Pres AND CEO, Dir | M - OptEx | $0.00 | -3,044 | 972.4K | -0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-07 | S | D | 413 | $30.08 | 54,274 | D | — | — | (F2) The weighted average sale price for the transaction reported was $30.08, and the range of prices were between $30.00 and $30.12. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2021-09-08 | S | D | 2,631 | $30.00 | 52,514 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-07 | M | A | 413 | $4.82 | 54,687 | D | — | — | |
| 4 | Common | Common Stock | 2021-09-08 | M | A | 2,631 | $4.82 | 56,905 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2021-09-07 | M | D | 413 | $0.00 | 975,032 | D | $4.82 · — to 2030-11-18 | 413 Common Stock | (F3) (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. |
| 6 | Derivative | Stock Option (Right to Buy) | 2021-09-08 | M | D | 2,631 | $0.00 | 972,401 | D | $4.82 · — to 2030-11-18 | 2,631 Common Stock | (F3) (A) 256,992 of the shares subject to the option vest on September 1, 2021, (B) 2,411 of the shares subject to the option vest on January 1, 2022 and 2,410 of the shares subject to the option vest on January 1 of each of 2023 and 2024 and (C) 23,143 of the shares subject to the option vest on the 1st day of each month (other than on September 1, 2021 and each of January 1, 2022, 2023 and 2024) following September 1, 2021, plus an additional 23 shares on September 1, 2024. Subject to, in each case of (A) - (C) above, the Reporting Person's continuous service on each applicable vesting date. The stock option is early exercisable. |